Combination of Endoglin and ASCVD Risk Assessment Improves Carotid Subclinical Atherosclerosis Recognition

Overview

Journal J Atheroscler Thromb

Date 2019 Aug 14

PMID 31406054

Citations 3

Authors

Qiaowei Li

Fan Lin

Douli Ke

Qiong Cheng

Yongzhi Gui

Yuyan Zhou

Yicheng Wu

Yinzhou Wang

Pengli Zhu

Affiliations

Soon will be listed here.

Abstract

Aim: Our study investigated the association between soluble endoglin and carotid subclinical atherosclerosis.

Methods: We used endoglin as an adjunct to atherosclerotic cardiovascular disease (ASCVD) risk, in recognition of carotid clinical atherosclerosis, in order to explore a new model to refine risk assessment. Out of 3,452 participants, 978 subjects with detected soluble endoglin were enrolled in a cross-sectional investigation in Fujian Province were enrolled. Soluble endoglin concentration in serum samples was evaluated using an enzyme-linked immunosorbent assay method. Carotid ultrasonography was used to detect intima-media thickness and carotid plaque.

Results: The mean 10-year ASCVD risk by the new Pooled Cohort Equations accounted for 10.04% (±12.35). The mean soluble endoglin level was 15.35 ng/ml (±6.64). Multivariable regression demonstrated that age, systolic blood pressure, diastolic blood pressure, total cholesterol, high density lipoprotein cholesterol, and serum uric acid were independent determinants of soluble endoglin. Adding tests of ASCVD and endoglin together, in parallel, will increase the sensitivity and decrease specificity in recognizing carotid subclinical atherosclerosis. Evaluating the added value of endoglin to the ASCVD risk model showed significantly improved discrimination with analysis of C-statistics, continuous net reclassification index and integrated discrimination index. Both ASCVD risk and soluble endoglin showed positively linear correlation with carotid intima-media thickness (cIMT) (β=0.006, P＜0.001; β=0.485, P＜0.001). Even with adjustment for other factors, the relationship between log-transformed soluble endoglin with cIMT was still significant (β=0.369, P＜0.001).

Conclusions: The combination of ASCVD risk and endoglin levels increases carotid atherosclerosis recognition.

Citing Articles

Low Plasma Levels of Soluble Endoglin and Cardiovascular Events in Patients Undergoing Coronary Angiography.

Saita E, Kishimoto Y, Aoyama M, Ohmori R, Kondo K, Momiyama Y Biomedicines. 2023; 11(11).

PMID: 38001975 PMC: 10669441. DOI: 10.3390/biomedicines11112975.

Membrane and soluble endoglin role in cardiovascular and metabolic disorders related to metabolic syndrome.

Vicen M, Igreja Sa I, Tripska K, Vitverova B, Najmanova I, Eissazadeh S Cell Mol Life Sci. 2020; 78(6):2405-2418.

PMID: 33185696 PMC: 11072708. DOI: 10.1007/s00018-020-03701-w.

Potential Role of Circulating Endoglin in Hypertension via the Upregulated Expression of BMP4.

Gallardo-Vara E, Gamella-Pozuelo L, Perez-Roque L, Bartha J, Garcia-Palmero I, Casal J Cells. 2020; 9(4).

PMID: 32316263 PMC: 7226995. DOI: 10.3390/cells9040988.

References

Blaha M, Cermanova M, Blaha V, Jarolim P, Andrys C, Blazek M . Elevated serum soluble endoglin (sCD105) decreased during extracorporeal elimination therapy for familial hypercholesterolemia. Atherosclerosis. 2007; 197(1):264-70. DOI: 10.1016/j.atherosclerosis.2007.04.022. View

Blazquez-Medela A, Garcia-Ortiz L, Gomez-Marcos M, Recio-Rodriguez J, Sanchez-Rodriguez A, Lopez-Novoa J . Increased plasma soluble endoglin levels as an indicator of cardiovascular alterations in hypertensive and diabetic patients. BMC Med. 2010; 8:86. PMC: 3012013. DOI: 10.1186/1741-7015-8-86. View

Naqvi T, Lee M . Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging. 2014; 7(10):1025-38. DOI: 10.1016/j.jcmg.2013.11.014. View

Blann A, Wang J, Wilson P, Kumar S . Serum levels of the TGF-beta receptor are increased in atherosclerosis. Atherosclerosis. 1996; 120(1-2):221-6. DOI: 10.1016/0021-9150(95)05713-7. View

Nambi V, Chambless L, Folsom A, He M, Hu Y, Mosley T . Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010; 55(15):1600-7. PMC: 2862308. DOI: 10.1016/j.jacc.2009.11.075. View

Cruz-Gonzalez I, Pabon P, Rodriguez-Barbero A, Martin-Moreiras J, Pericacho M, Sanchez P . Identification of serum endoglin as a novel prognostic marker after acute myocardial infarction. J Cell Mol Med. 2008; 12(3):955-61. PMC: 4401139. DOI: 10.1111/j.1582-4934.2008.00156.x. View

Doghish A, Bassyouni A, Mahfouz M, Abd El-Aziz H, Zakaria R . Plasma endoglin in Type2 diabetic patients with nephropathy. Diabetes Metab Syndr. 2019; 13(1):764-768. DOI: 10.1016/j.dsx.2018.11.058. View

Zhou M, Wang H, Zhu J, Chen W, Wang L, Liu S . Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the Global Burden of Disease Study 2013. Lancet. 2015; 387(10015):251-72. DOI: 10.1016/S0140-6736(15)00551-6. View

Celik N, Cinaz P, Bideci A, Derinkuyu B, Emeksiz H, Doger E . Endoglin and obestatin levels, cardiometabolic risk factors and subclinical atherosclerosis in children aged 10-18 years. J Pediatr Endocrinol Metab. 2016; 29(10):1173-1180. DOI: 10.1515/jpem-2016-0024. View

10.

Zureik M, Temmar M, Adamopoulos C, Bureau J, Courbon D, Thomas F . Carotid plaques, but not common carotid intima-media thickness, are independently associated with aortic stiffness. J Hypertens. 2002; 20(1):85-93. DOI: 10.1097/00004872-200201000-00013. View

11.

Charytan D, Helfand A, MacDonald B, Cinelli A, Kalluri R, Zeisberg E . Circulating endoglin concentration is not elevated in chronic kidney disease. PLoS One. 2011; 6(8):e23718. PMC: 3158786. DOI: 10.1371/journal.pone.0023718. View

12.

Stein J, Korcarz C, Hurst R, Lonn E, Kendall C, Mohler E . Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for.... J Am Soc Echocardiogr. 2008; 21(2):93-111. DOI: 10.1016/j.echo.2007.11.011. View

13.

Yang G, Wang Y, Zeng Y, Gao G, Liang X, Zhou M . Rapid health transition in China, 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2013; 381(9882):1987-2015. PMC: 7159289. DOI: 10.1016/S0140-6736(13)61097-1. View

14.

Kandula N, Kanaya A, Liu K, Lee J, Herrington D, Hulley S . Association of 10-year and lifetime predicted cardiovascular disease risk with subclinical atherosclerosis in South Asians: findings from the Mediators of Atherosclerosis in South Asians Living in America (MASALA) study. J Am Heart Assoc. 2014; 3(5):e001117. PMC: 4323809. DOI: 10.1161/JAHA.114.001117. View

15.

Nikuei P, Rajaei M, Malekzadeh K, Nejatizadeh A, Mohseni F, Atashabparvar A . Accuracy of Soluble Endoglin for Diagnosis of Preeclampsia and its Severity. Iran Biomed J. 2017; 21(5):312-30. PMC: 5548963. DOI: 10.18869/acadpub.ibj.21.5.312. View

16.

Naqvi T, Mendoza F, Rafii F, Gransar H, Guerra M, Lepor N . High prevalence of ultrasound detected carotid atherosclerosis in subjects with low Framingham risk score: potential implications for screening for subclinical atherosclerosis. J Am Soc Echocardiogr. 2010; 23(8):809-15. DOI: 10.1016/j.echo.2010.05.005. View

17.

Levey A, Bosch J, Lewis J, Greene T, Rogers N, Roth D . A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999; 130(6):461-70. DOI: 10.7326/0003-4819-130-6-199903160-00002. View

18.

Venkatesha S, Toporsian M, Lam C, Hanai J, Mammoto T, Kim Y . Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med. 2006; 12(6):642-9. DOI: 10.1038/nm1429. View

19.

Saita E, Miura K, Suzuki-Sugihara N, Miyata K, Ikemura N, Ohmori R . Plasma Soluble Endoglin Levels Are Inversely Associated With the Severity of Coronary Atherosclerosis-Brief Report. Arterioscler Thromb Vasc Biol. 2016; 37(1):49-52. DOI: 10.1161/ATVBAHA.116.308494. View

20.

Marathe P, Gao H, Close K . American Diabetes Association Standards of Medical Care in Diabetes 2017. J Diabetes. 2017; 9(4):320-324. DOI: 10.1111/1753-0407.12524. View